Source-grounded facts extracted from Praxis Precision Medicines, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Praxis Precision Medicines, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-10 meeting.
“The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 24,054,017 824,318 29,929 1,815,967”
Praxis Precision Medicines, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm at the 2026-06-10 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 26,667,376 39,285 17,570 0”
Praxis Precision Medicines, Inc. shareholders approved Election of Class III Directors at the 2026-06-10 meeting.
“The Company’s stockholders elected Gregory Norden, Marcio Souza and William Young to serve as Class III members of the Board of Directors of the Company until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows: Class III Director Nominees Votes For Votes Withheld Broker Non-Vote Gregory Norden 24,597,327 310,937 1,815,967 Marcio Souza 24,771,396 136,868 1,815,967 William Young 21,293,535 3,614,729 1,815,967”
Praxis Precision Medicines, Inc. reported financial results for the first quarter of 2026.
“Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
Praxis Precision Medicines, Inc. reported the first quarter 2024 results: net income $39.6 million.
“Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”
Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full-year 2023.
“On March 5, 2024, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2023.”
Praxis Precision Medicines, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75,000,000 (effective 2023-12-07).
“On December 7, 2023, Praxis Precision Medicines, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with an aggregate offering price of up to $75,000,000, from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent.”
Praxis Precision Medicines, Inc.: Filing of Certificate of Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2023-11-28).
“On November 28, 2023, Praxis Precision Medicines, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the “Reverse Stock Split”).”
Praxis Precision Medicines, Inc. reported the three months ended September 30, 2023 results: revenue $0.5 million, net income net loss of $24.6 million.
“offerings of shares of Praxis’ common stock, partially offset by cash used in operations of $87.3 million during the nine months ended September 30, 2023. Praxis recognized $0.5 million in collaboration revenue during the three months ended September 30, 2023, related to its Option and License Agreement with UCB. Research and development expenses were $17.3”
Praxis Precision Medicines, Inc. shareholders approved Proposal to adjourn the Special Meeting to a later date, if necessary, to permit further solicitation of proxies in connection with the Reverse Stock Split Proposal at the 2023-11-06 meeting.
“The Company’s stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 85,270,203 22,026,296 15,285 0”
Praxis Precision Medicines, Inc. shareholders approved Approval of amendments to the Amended and Restated Certificate of Incorporation to give the Board discretionary authority to effect a reverse stock split at a ratio ranging from 1-for-5 to 1-for-25 at the 2023-11-06 meeting.
“The Company’s stockholders approved amendments to the Company’s Amended and Restated Certificate of Incorporation to give the Company’s Board of Directors discretionary authority to effect a reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.0001 per share, at a ratio ranging from any whole number between 1-for-5 and 1-for-25, as determined by the Company’s Board of Directors in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”), with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 85,952,274 21,357,155 2,355 0”
Praxis Precision Medicines, Inc. reported financial results for second quarter 2023.
“Praxis Precision Medicines, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023.”
Praxis Precision Medicines, Inc. terminated Open Market Sale Agreement with Jefferies LLC (effective 2023-06-15).
“On June 15, 2023, the Company delivered written notice to Jefferies to terminate the Sales Agreement pursuant to Section 7(b) thereof.”
Praxis Precision Medicines, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-12 meeting.
“Proposal 3 – Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 29,790,931 7,738,170 1,033,594 5,199,545”
Praxis Precision Medicines, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm at the 2023-06-12 meeting.
“Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company ’ s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 47,578,569 18,327 61,908 0”
Praxis Precision Medicines, Inc. shareholders approved Election of Class III Directors at the 2023-06-12 meeting.
“Proposal 1 – Election of Class III Directors The Company’s stockholders elected Gregory Norden, Marcio Souza and William Young to serve as Class III members of the Board of Directors of the Company (the “Board”) until the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows: Class III Director Nominees Votes For Votes Withheld Broker Non-Vote Gregory Norden 35,093,179 7,366,080 5,199,545 Marcio Souza 35,151,003 7,308,256 5,199,545 William Young 18,353,865 24,105,394 5,199,545”
Praxis Precision Medicines, Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million.
“Praxis recognized $0.7 million in collaboration revenue during the three months ended March 31, 2023”
Nicole Sweeny departed as Chief Commercial Officer at Praxis Precision Medicines, Inc..
“On March 17, 2023, Nicole Sweeny, Chief Commercial Officer of Praxis Precision Medicines, Inc. (the “Company”), and the Company determined that, considering the current priorities of the Company, Ms. Sweeny would depart from the Company, effective March 31, 2023.”
Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full year 2022.
“On February 7, 2023 , Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.”
Praxis Precision Medicines, Inc. reported financial results for the third quarter of 2022.
“On November 9, 2022, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.”
Stefan Vitorovic resigned as Director at Praxis Precision Medicines, Inc..
“On August 10, 2022, Stefan Vitorovic, a member of the board of directors (the “Board”) of Praxis Precision Medicines, Inc. (the “Company”), notified the Board of his intention to resign from the Board, effective August 12, 2022.”
Bernard Ravina changed role as Chief Medical Officer at Praxis Precision Medicines, Inc..
“On July 21, 2022, Bernard Ravina, Chief Medical Officer of Praxis Precision Medicines, Inc. (the “ Company ”), who is currently on leave attending to family medical matters, and the Company mutually decided that Dr. Ravina will transition from his full-time position as Chief Medical Officer to a part-time role as strategic advisor to the Company on August 1, 2022.”
Jill DeSimone was elected as Class I director at Praxis Precision Medicines, Inc..
“elected Jill DeSimone to the Board as a Class I director, effective May 23, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.